Photoaffinity analogues of farnesyl pyrophosphate transferable by protein farnesyl transferaseCHEHADE, Kareem A. H; KIEGIEL, Katarzyna; ISAACS, Richard J et al.Journal of the American Chemical Society. 2002, Vol 124, Num 28, pp 8206-8219, issn 0002-7863Article

Cloning, Solubilization, and Characterization of Squalene Synthase from Thermosynechococcus elongatus BP-1LEE, Sungwon; DALE POULTER, C.Journal of bacteriology. 2008, Vol 190, Num 11, pp 3808-3816, issn 0021-9193, 9 p.Article

Farnesyltransferase inihibitors in hematologic malignanciesHAROUSSEAU, Jean-Luc.Blood reviews. 2007, Vol 21, Num 4, pp 173-182, issn 0268-960X, 10 p.Article

Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitorsJINGXUAN PAN; JIM YEUNG, Sai-Ching.Cancer research (Baltimore). 2005, Vol 65, Num 20, pp 9109-9112, issn 0008-5472, 4 p.Article

Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor modelsMANNE, Veeraswamy; LEE, Francis Y. F; TAI WAI WONG et al.Cancer research (Baltimore). 2004, Vol 64, Num 11, pp 3974-3980, issn 0008-5472, 7 p.Article

Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1DUHADAWAY, James B; WEI DU; DONOVER, Scott et al.Oncogene (Basingstoke). 2003, Vol 22, Num 23, pp 3578-3588, issn 0950-9232, 11 p.Article

Mutagenesis and biochemical studies on AuaA confirmed the importance of the two conserved aspartate-rich motifs and suggested difference in the amino acids for substrate binding in membrane-bound prenyltransferasesSTEC, Edyta; LI, Shu-Ming.Archives of microbiology. 2012, Vol 194, Num 7, pp 589-595, issn 0302-8933, 7 p.Article

Protein prenylation, et cetera : Signal transduction in two dimensionsGELB, M. H.Science (Washington, D.C.). 1997, Vol 275, Num 5307, pp 1750-1751, issn 0036-8075Article

Farnesyl transferase inhibitor resistance probed by target mutagenesisRAZ, Tal; NARDI, Valentina; AZAM, Mohammad et al.Blood. 2007, Vol 110, Num 6, pp 2102-2109, issn 0006-4971, 8 p.Article

1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthaseAMIN, D; CORNELL, S. A; PERRONE, M. H et al.Arzneimittel-Forschung. 1996, Vol 46, Num 8, pp 759-762, issn 0004-4172Article

Characterization of a Squalene Synthase from the Thraustochytrid Microalga Aurantiochytrium sp. KRS101HONG, Won-Kyung; HEO, Sun-Yeon; PARK, Hye-Mi et al.Journal of microbiology and biotechnology. 2013, Vol 23, Num 6, pp 759-765, issn 1017-7825, 7 p.Article

Kinetic characterization of squalene synthase from Trypanosoma cruzi: Selective inhibition by quinuclidine derivativesSEALEY-CARDONA, Marco; CAMMERER, Simon; JONES, Simon et al.Antimicrobial agents and chemotherapy. 2007, Vol 51, Num 6, pp 2123-2129, issn 0066-4804, 7 p.Article

Analysis of squalene synthase expression during the development of Ganoderma lucidumZHAO, M. W; ZHONG, J. Y; LIANG, W. Q et al.Journal of microbiology and biotechnology. 2004, Vol 14, Num 1, pp 116-120, issn 1017-7825, 5 p.Article

Farnesyl transferase inhibitors in myeloid malignanciesLANCET, Jeffrey E; KARP, Judith E.Blood reviews. 2003, Vol 17, Num 3, pp 123-129, issn 0268-960X, 7 p.Article

Les inhibiteurs de la farnésyl-transférase (anti-ras) : une nouvelle classe d'anti-cancéreux = Farnesyl transferase inhibitors (anti-ras).A new class of anticancer drugsLEVY, R.La Presse médicale (1983). 1995, Vol 24, Num 15, pp 725-729, issn 0755-4982Article

Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic functionSIEGEL-LAKHAI, Wandena S; CRUL, Mirjam; DE PORRE, Peter et al.Journal of clinical oncology. 2006, Vol 24, Num 28, pp 4558-4564, issn 0732-183X, 7 p.Article

Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft modelsFERGUSON, Debra; RODRIGUEZ, Luis E; HAIYING ZHANG et al.Clinical cancer research. 2005, Vol 11, Num 8, pp 3045-3054, issn 1078-0432, 10 p.Article

A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumorsMOULDER, Stacy L; MAHANY, John J; SULLIVAN, Daniel M et al.Clinical cancer research. 2004, Vol 10, Num 21, pp 7127-7135, issn 1078-0432, 9 p.Article

Farnesyl protein transferase inhibitors targeting the catalytic zinc for enhanced bindingNJOROGE, F. George; VIBULBHAN, Bancha; PINTO, Patrick et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 23, pp 5877-5880, issn 0960-894X, 4 p.Article

Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibitionKAMASANI, Uma; MINZHOU HUANG; DUHADAWAY, James B et al.Cancer research (Baltimore). 2004, Vol 64, Num 22, pp 8389-8396, issn 0008-5472, 8 p.Article

Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapyLANCET, Jeffrey E; KARP, Judith E.Blood. 2003, Vol 102, Num 12, pp 3880-3889, issn 0006-4971, 10 p.Article

Assessing the future landscape in myeloid malignancies: evolving insights on farnesyltransferase inhibitorsROSENBLATT, Joseph D; ROWE, Jacob M.Seminars in hematology. 2002, Vol 39, Num 3, issn 0037-1963, 40 p., SUP2Serial Issue

Advancing the treatment of hematologic malignancies through the development of targeted interventionsTALLMAN, Martin S.Seminars in hematology. 2002, Vol 39, Num 4, issn 0037-1963, 39 p., SUP3Serial Issue

Bench-to-bedside studies of radiation sensitization by Farnesyltransferase InhibitorsBRUNNER, Thomas B; YUQUAN SHI; GUPTA, Anjali K et al.Recent research developments in cancer : Vol. 4 (2002) - Part II. Recent research developments in cancer. 2002, pp 613-624, isbn 81-7895-051-0, 12 p.Book Chapter

Targeting the Ras signaling pathway : a rational, mechanism-based treatment for hematologic malignancies?REUTER, C. W. M; MORGAN, M. A; BERGMANN, L et al.Blood. 2000, Vol 96, Num 5, pp 1655-1669, issn 0006-4971Article